Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide-Reference-Cited by-同舟云学术

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide

Published:2019-04-16 Issue: Volume: Page:
ISSN:1019-6439
Container-title:International Journal of Oncology
language:
Short-container-title:Int J Oncol

Author:

Forte Iris¹,Indovina Paola²,Iannuzzi Carmelina¹,Cirillo Donatella¹,Di Marzo Domenico¹,Barone Daniela¹,Capone Francesca³,Pentimalli Francesca¹,Giordano Antonio²

Affiliation:

1. Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori ‑ IRCCS ‑ Fondazione G. Pascale, I‑80131 Napoli, Italy

2. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA

3. Experimental Pharmacology Unit, Istituto Nazionale Tumori ‑ IRCCS ‑ Fondazione G. Pascale, I‑80131 Napoli, Italy

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma;2024-08-14

2. Targeting drug resistance in glioblastoma (Review);International Journal of Oncology;2024-07-09

3. A Synopsis of Biomarkers in Glioblastoma: Past and Present;Current Issues in Molecular Biology;2024-07-03

4. Evidence That a Peptide-Drug/p53 Gene Complex Promotes Cognate Gene Expression and Inhibits the Viability of Glioblastoma Cells;Pharmaceutics;2024-06-08

5. Cellular senescence in glioma;Journal of Neuro-Oncology;2023-07-17